1. Home
  2. PRHI vs TPST Comparison

PRHI vs TPST Comparison

Compare PRHI & TPST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

PRHI

Presurance Holdings Inc.

HOLD

Current Price

$4.45

Market Cap

18.7M

Sector

Finance

ML Signal

HOLD

Logo Tempest Therapeutics Inc.

TPST

Tempest Therapeutics Inc.

HOLD

Current Price

$1.10

Market Cap

15.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PRHI
TPST
Founded
2009
2011
Country
United States
United States
Employees
12
N/A
Industry
Property-Casualty Insurers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
18.7M
15.6M
IPO Year
N/A
2012

Fundamental Metrics

Financial Performance
Metric
PRHI
TPST
Price
$4.45
$1.10
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$11.00
AVG Volume (30 Days)
2.8K
121.6K
Earning Date
05-13-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$295,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.48
$0.84
52 Week High
$6.40
$12.22

Technical Indicators

Market Signals
Indicator
PRHI
TPST
Relative Strength Index (RSI) 41.15 58.83
Support Level $0.60 $1.02
Resistance Level $5.84 $1.09
Average True Range (ATR) 0.31 0.06
MACD -0.16 0.03
Stochastic Oscillator 10.00 85.46

Price Performance

Historical Comparison
PRHI
TPST

About PRHI Presurance Holdings Inc.

Presurance Holdings Inc is an insurance holding company that markets and services product offerings through specialty personal insurance lines of business. Through its personal insurance lines, it offers homeowners insurance and dwelling fire insurance products to individuals in several states. The specialty homeowners insurance product line is comprised of low-value dwelling insurance tailored for owners of lower valued homes, which it offers in Texas, Illinois and Indiana. Through commercial insurance lines, it offers coverage for both commercial property and commercial liability and also offered coverage for commercial automobiles and workers' compensation. Its revenues are derived from premiums earned from insurance operations.

About TPST Tempest Therapeutics Inc.

Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets. Company's small-molecule product candidate, amezalpat (previously known as TPST-1120), has completed a Phase 2 study in first-line hepatocellular carcinoma and the second small-molecule product candidate is TPST-1495, plans to initiate a Phase 2 study for in familial adenomatous polyposis.

Share on Social Networks: